Question:
What clinical data changes this?
Is it Validation that FTO is inhibited in humans? Is it Tumour reduction without toxicity? something along those lines that can be determined fairly early into a trial, or is it likely OS results which might be 12-24 months post first patient being dosed in a P2
I think everyone knows and is waiting on "clinical data" but the answer of what Clinical data is needed might help people determine timelines and value inflection points. Something RAC is most likely not going to tell us
General Comments / Chat, page-8630
-
- There are more pages in this discussion • 2,544 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.84 |
Change
-0.020(1.08%) |
Mkt cap ! $316.8M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.91 | $1.84 | $111.1K | 59.86K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 550 | $1.82 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.84 | 104 | 1 |
View Market Depth
| Last trade - 13.32pm 19/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |